# US 2021/0275475 A1 · Novel ketogenic compounds, compositions, methods and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275475 A1
- Document ID: US20210275475A1
- Status: Published application
- Kind: A1
- Application number: 17/251,440
- Filed: 2019-06-04
- Published: 2021-09-09
- Earliest claimed: 2018-06-12
- Assignees: Ketofibe (9211-3133 Quebec Inc.)
- Applicants: Ketofibe (9211-3133 Quebec Inc.)
- Inventors: Steve Kerr; Mylvaganam Murugesapillai; Alex Millin
- Web page: https://patentgrep.com/patent/US20210275475A1

## CPC

- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/722: Chitin, chitosan
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 31/047: having two or more hydroxy groups, e.g. sorbitol
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K 47/38: Cellulose; Derivatives thereof
- A61K 47/61: the organic macromolecular compound being a polysaccharide or a derivative thereof
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- C08B 15/005: {Crosslinking of cellulose derivatives}
- C08B 37/003: {Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof}
- C08J 3/075: Macromolecular gels
- C08L 1/286: {substituted with acid radicals, e.g. carboxymethyl cellulose [CMC] (C08L1/282 takes precedence)}
- C08L 5/08: Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
- C08J 2301/28: Alkyl ethers
- C08J 2305/08: Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
- C08J: WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H (working, e.g. shaping, of plastics B29)
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)

## Abstract

The present disclosure relates to compounds comprising β-hydroxybutyric acid, and a weakly basic polymer. The disclosure also includes methods for inducing nutritional ketosis comprising administering the compounds or compositions comprising the compounds to a mammal in need thereof.

## Claims

### Claim 1

A compound, comprising:
a) β-hydroxybutyric acid (BHB); and
b) an ingestible and non-digestible weakly basic polymer, comprising monomers having weak base functional groups.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein the molar ratio of BHB to the weak base monomer is about 1:1.

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5 (depends on 4)

The compound of claim 4, wherein the BHB is D-BHB.

### Claim 6 (depends on 1)

The compound of claim 1, wherein the weakly basic polymer has a pKb of between about 4 to about 10.5.

### Claim 7 (depends on 1)

The compound of claim 1, wherein the weakly basic polymer is sodium-carboxymethylcellulose or chitosan.

### Claim 8 (depends on 1)

The compound of claim 1 wherein the compound has the formula
[(weakly basic monomer)+(BHB)−]x
wherein x is an integer between about 2 and about 1000.

### Claim 9 (depends on 1)

The compound of claim 1, wherein the weakly basic polymer has the formula
[(glucNH2)n(glucNHAc)m]
wherein
(glucNH2) is a glucosamine residue,
(glucNHAc) is an N-acetylglucosamine residue;
“m” ranges from 0% to about 30% of the total residues;
“n” ranges from 70% to about 100% of the total residues;
wherein the total number of residues is between about 2 to about 1000.

### Claim 10 (depends on 9)

The compound of claim 9, wherein the polymer has a mass of between about 9 kD to about 300 kD.

### Claim 11 (depends on 9)

The compound of claim 9, wherein the compound has the structure:

### Claim 12 (depends on 9)

The compound of claim 9, wherein the weakly basic polymer has the formula
[(glu(CH2CO2)xMx[n(glu)m]
wherein
[glu(CH2CO2)xMx] are carboxymethyl glucose residues,
glu are glucose residues;
x=1 or 2 or 3 and M are cations with charge, +1 or +2 or +3;
“m” ranges from 0% to about 30% of the total residues;
“n” ranges from 70% to about 100% of the total residues;
wherein the total number of residues is between about 2 to about 1000.

### Claim 13 (depends on 12)

The compound of claim 12, wherein the polymer has a mass of between about 9 kD to about 300 kD.

### Claim 14 (depends on 12)

The compound of claim 12, wherein the compound has the structure

### Claim 15 (depends on 1)

The compound of claim 1, wherein the BHB has an intolerable taste and the compound is substantially free of the intolerable taste.

### Claim 16 (depends on 15)

The compound of claim 15, wherein the concentration of the BHB in a solution is at least about 1.0% (weight/volume).

### Claim 17

A hydrogel comprising,
a) β-hydroxybutyric acid (BHB);
b) an ingestible and non-digestible weakly basic polymer, comprising monomers having weak base functional groups; and
c) water,
wherein the molar ratio of BHB to the weak base functional group is about 1:1.

### Claim 18 (depends on 15)

The hydrogel of claim 15, wherein the hydrogel further comprises additional ketogenic precursors.

### Claim 19 (depends on 17)

The hydrogel of claim 17, wherein the ketogenic precursor is poly-BHB, oligomers of BHB, 1,3-butanediol, and/or acetoacetic acid or esters thereof.

### Claim 20 (depends on 17)

The hydrogel of claim 17, further comprising additional BHB.

### Claim 21 (depends on 20)

The hydrogel of claim 20, wherein the ratio of BHB to weak base functional groups is greater than 1 to 1.

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24 (depends on 23)

The hydrogel of claim 23, wherein the ratio of BHB to weak base functional groups is greater than about 10 to about 1.

### Claim 25 (depends on 17)

The hydrogel of claim 17, wherein the BHB is D-BHB.

### Claim 26 (depends on 1)

A method for increasing ketone levels comprising administering to a subject in need thereof a therapeutically effective amount of a compound as claimed in claim 1, wherein BHB has an intolerable taste and the compound or hydrogel is substantially free of the intolerable-taste.

### Claim 27 (depends on 20)

The method according to claim 20, for promoting ketosis, for promoting weight loss or suppressing appetite, for preventing or treating neurodegenerative conditions, for preventing or treating traumatic brain injuries, for treating a condition caused by muscle impairment or muscle fatigue, for the prevention or the improvement of treatment for cancer, for treating diabetes, or for regulating or lowering blood glucose levels.
